The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) is a hormone produced in the upper gut and secreted to the circulation in response to the ingestion of foods, especially fatty foods. Growing evidence supports the physiological and pharmacological relevance of GIP in obesity. In an obesity setting, inhibition of endogenous GIP or its receptor leads to decreased energy intake, increased energy expenditure, or both, eventually causing weight loss. Further, supraphysiological dosing of exogenous long-lasting GIP agonists alters energy balance and has a marked antiobesity effect. This remarkable yet paradoxical antiobesity effect is suggested to occur primarily via the brain. The brain is capable of regulating both energy intake and expenditure and plays a critical role in human obesity. In addition, the GIP receptor is widely distributed throughout the brain, including areas responsible for energy homeostasis. Recent studies have uncovered previously underappreciated roles of the GIP receptor in the brain in the context of obesity. This article highlights how the GIP receptor expressed by the brain impacts obesity-related pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583 · cited 1×
“Within the ARC are two distinct prototypical neuronal populations that yield opposing effects on energy balance: the orexigenic neurons expressing neuropeptide Y and Agouti-related peptide (AgRP/NPY neurons) that promote feeding behavior when activated and the anorexigenic neurons expressing proopiomelanocortin (POMC…”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 7×
“ARC neurons can access the adjacent median eminence, which lacks a functional blood-brain barrier (BBB), permitting ARC neurons to sense bloodborne factors from the periphery (37).”
BackgroundInfluentialElmquist, J. K., Elias, C. F., & Saper, C. B. (1999) · Neuron · doi:10.1016/s0896-6273(00)81084-3 · Cited by 1,160
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“Although favorable data to support this model accumulated for many years, direct evidence supporting a role for GIP as an obesogenic signal initially came from a seminal study by Seino and colleagues (5).”
BackgroundInfluentialDiabetes, Obesity, and the Brain
Schwartz, M. W., & Porte, D. (2005) · Science · doi:10.1126/science.1104344 · Cited by 841
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“In addition, GLP-1/GIP hybrid peptides have been shown to induce marked weight loss in preclinical and clinical settings (31,32).”
BackgroundScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 7×
“Further, a dual GLP-1/GIPR agonist more effectively reduces proinflammatory cytokine levels in the brain in a mouse model of Alzheimer disease than the GLP-1R agonist alone (81), suggesting that the GIP moiety potentiates the anti-inflammatory effect of the GLP-1 agonist.”
BackgroundInfluentialUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“In addition, GLP-1/GIP hybrid peptides have been shown to induce marked weight loss in preclinical and clinical settings (31,32).”
BackgroundLeptin and the endocrine control of energy balance
Friedman, J. M. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0095-y · Cited by 661 · cited 2×
“Leptin is a hormone produced and secreted by adipocytes in proportion to fat mass and acts directly on neurons in the CNS (72).”
BackgroundLeptin and the maintenance of elevated body weight
Pan, W. W., & Myers, M. G. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.168 · Cited by 344
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 6×
“(48) used single-cell RNA-seq to identify the cell types expressing GIPR and found that GIPR is expressed not only by neurons but also by other nonneural cells such as vascular and glial cells in the mouse hypothalamus.”
BackgroundInfluentialZhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322 · cited 19×
“Importantly, the weight loss effect of ICV-administered acyl-GIP was blunted in brain-specific GIPR knockout mice (29), suggesting that this effect occurs via GIPR in the CNS. Interestingly, acyl-GIP stimulates c-fos induction (a marker for neural activation) in the ARC (29) where GIPR is expressed (48).”
BackgroundInfluentialGIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · cited 1×
“Furthermore, GIP promotes fat deposition in the adipose tissues (4).”
BackgroundCommon variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations
GIANT consortium, Okada, Y., Kubo, M., Ohmiya, H., Takahashi, A., Kumasaka, N., Hosono, N., Maeda, S., Wen, W., Dorajoo, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.1086 · Cited by 256
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · cited 1×
“Instead, negative energy balance is induced by administration of long-lasting GIP derivatives (28,29) or transgenic overexpression of GIP (30).”
BackgroundKim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182 · cited 2×
“Instead, negative energy balance is induced by administration of long-lasting GIP derivatives (28,29) or transgenic overexpression of GIP (30).”
BackgroundAlthage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · cited 1×
“Many methods of inhibition have been tested, including GIP deficiency (9), ablation of GIP-producing K cells (10), neutralizing antibodies against GIP/GIPR (11–14), GIP vaccination (15–17), and pharmacological inhibition of GIPR (18).”
MethodKillion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Vaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · cited 1×
“This remains true for GIP-mediated weight loss, which induces increased energy expenditure, decreased food intake, or both (35).”
BackgroundWheeler, M. B., Gelling, R. W., McIntosh, C. H., Georgiou, J., Brown, J. C., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.10.7664683 · Cited by 130
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · cited 10×
“However, centrally expressed GIP was not detected in other studies (13,47,56).”
BackgroundMethodResultSelf-citationGögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
Timper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70 · cited 1×
“Moreover, GIPR deficiency in bone marrow myeloid cells increases expression of proinflammatory factors and reduces insulin sensitivity (80).”
BackgroundPharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53
Paratore, S., Teresa Ciotti, M., Basille, M., Vaudry, D., Gentile, A., Parenti, R., Calissano, P., & Cavallaro, S. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152411798047771 · Cited by 41 · cited 1×
“Another group also detected widespread Gip mRNA by in situ hybridization in the adult rat brain (44).”
BackgroundGut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38 · cited 4×
“Acute inhibition of GIPR via a centrally delivered neutralizing GIPR antibody also reduced IL-6 mRNA in the hypothalamus (49).”
BackgroundMethodInfluentialSelf-citationPro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Research works printed but not linked: 50
- Holst, 2013, Is there a place for incretin therapies in obesity and prediabetes?, Trends Endocrinol Metab, 24, 145, 10.1016/j.tem.2013.01.004 · DOI
- Marks, 2020, The early history of GIP 1969-2000: from enterogastrone to major metabolic hormone, Peptides, 125, 170276, 10.1016/j.peptides.2020.170276 · DOI
- Creutzfeldt, 1978, Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels, Diabetologia, 14, 15, 10.1007/BF00429703 · DOI · Paper page
- Bailey, 1986, Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets, Acta Endocrinol (Copenh), 112, 224, 10.1530/acta.0.1120224 · DOI · Paper page
- Polak, 1975, Gastrointestinal apudosis in obese hyperglycaemic mice, Virchows Arch B Cell Pathol Incl Mol Pathol, 19, 135, 10.1007/BF02889363 · DOI
- Nasteska, 2014, Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, 63, 2332, 10.2337/db13-1563 · DOI · Paper page
- Irwin, 2009, Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes, Biol Chem, 390, 75, 10.1515/BC.2009.002 · DOI · Paper page
- Montgomery, 2010, Active immunization against (Pro(3))GIP improves metabolic status in high-fat-fed mice, Diabetes Obes Metab, 12, 744, 10.1111/j.1463-1326.2010.01228.x · DOI · Paper page
- Nakamura, 2018, Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice, Obes Sci Pract, 4, 194, 10.1002/osp4.164 · DOI · Paper page
- Dorajoo, 2012, Replication of 13 obesity loci among Singaporean Chinese, Malay and Asian-Indian populations, Int J Obes (Lond), 36, 159, 10.1038/ijo.2011.86 · DOI
- Wen, 2012, Meta-analysis identifies common variants associated with body mass index in east Asians, Nat Genet, 44, 307, 10.1038/ng.1087 · DOI · Paper page
- Turcot, 2018, Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity, Nat Genet, 50, 26, 10.1038/s41588-017-0011-x · DOI · Paper page
- Woods, 1981, Peptides and the control of meal size, Diabetologia, 20, 305, 10.1007/BF00254497 · DOI
- Ambati, 2011, GIP-dependent expression of hypothalamic genes, Physiol Res, 60, 941, 10.33549/physiolres.932151 · DOI · Paper page
- NamKoong, 2017, Central administration of GLP-1 and GIP decreases feeding in mice, Biochem Biophys Res Commun, 490, 247, 10.1016/j.bbrc.2017.06.031 · DOI · Paper page
- Nauck, 2020, No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects, Peptides, 125, 170176, 10.1016/j.peptides.2019.170176 · DOI
- Rodríguez, 2010, The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid, Peptides, 31, 757, 10.1016/j.peptides.2010.01.003 · DOI · Paper page
- Hetherington, 1940, Hypothalamic lesions and adiposity in the rat, Anat Rec, 78, 149, 10.1002/ar.1090780203 · DOI · Paper page
- Farooqi, 2008, Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity, Nat Clin Pract Endocrinol Metab, 4, 569, 10.1038/ncpendmet0966 · DOI · Paper page
- Kaplan, 1994, Gastric inhibitory polypeptide (GIP) binding sites in rat brain, Peptides, 15, 297, 10.1016/0196-9781(94)90016-7 · DOI
- Regard, 2008, Anatomical profiling of G protein-coupled receptor expression, Cell, 135, 561, 10.1016/j.cell.2008.08.040 · DOI · Paper page
- Bates, 2012, Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(−/−) mice, Diabetes, 61, 40, 10.2337/db11-1060 · DOI · Paper page
- Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain, Endocrinology, 133, 2861, 10.1210/endo.133.6.8243312 · DOI · Paper page
- Lockie, 2012, Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling, Diabetes, 61, 2753, 10.2337/db11-1556 · DOI · Paper page
- Christensen, 2015, Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes, Int J Obes (Lond), 39, 1651, 10.1038/ijo.2015.136 · DOI
- Glage, 2011, Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats, Fluids Barriers CNS, 8, 18, 10.1186/2045-8118-8-18 · DOI
- Lee, 2013, CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer’s disease, J Alzheimers Dis Parkinsonism, 3, 128
- Nyberg, 2007, Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain, J Neurosci Res, 85, 2099, 10.1002/jnr.21349 · DOI · Paper page
- Adriaenssens, 2020, The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170194, 10.1016/j.peptides.2019.170194 · DOI · Paper page
- Papatheodorou, 2018, Expression Atlas: gene and protein expression across multiple studies and organisms, Nucleic Acids Res, 46, D246, 10.1093/nar/gkx1158 · DOI · Paper page
- Zhang, 2020, GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models, Peptides, 125, 170184, 10.1016/j.peptides.2019.170184 · DOI · Paper page
- Ravn, 2013, Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor, J Biol Chem, 288, 19760, 10.1074/jbc.M112.426288 · DOI · Paper page
- Ryan, 2012, Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity, Cell Metab, 15, 137, 10.1016/j.cmet.2011.12.013 · DOI · Paper page
- Könner, 2012, Selective insulin and leptin resistance in metabolic disorders, Cell Metab, 16, 144, 10.1016/j.cmet.2012.07.004 · DOI · Paper page
- Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet–fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
- Chen, 2015, Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice, Am J Physiol Endocrinol Metab, 308, E414, 10.1152/ajpendo.00418.2014 · DOI · Paper page
- Beaudry, 2019, Physiological roles of the GIP receptor in murine brown adipose tissue, Mol Metab, 28, 14, 10.1016/j.molmet.2019.08.006 · DOI · Paper page
- Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
- Lamont, 2008, Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice, Diabetes, 57, 190, 10.2337/db07-1202 · DOI · Paper page
- Kaneko, 2016, Neuronal Rap1 regulates energy balance, glucose homeostasis, and leptin actions, Cell Rep, 16, 3003, 10.1016/j.celrep.2016.08.039 · DOI · Paper page
- Fukuda, 2011, Induction of leptin resistance by activation of cAMP-Epac signaling, Cell Metab, 13, 331, 10.1016/j.cmet.2011.01.016 · DOI · Paper page
- Gloerich, 2010, Epac: defining a new mechanism for cAMP action, Annu Rev Pharmacol Toxicol, 50, 355, 10.1146/annurev.pharmtox.010909.105714 · DOI · Paper page
- Sands, 2006, Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells, Mol Cell Biol, 26, 6333, 10.1128/MCB.00207-06 · DOI · Paper page
- Armstrong, 2020, The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY, Nucleic Acids Res, 48, D1006
- Maskery, 2020, The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease, Am J Alzheimers Dis Other Demen, 35, 1533317520953041, 10.1177/1533317520953041 · DOI · Paper page
- Siegel, 1985, Stimulation of insulin release in isolated rat islets by GIP in physiological concentrations and its relation to islet cyclic AMP content, Diabetologia, 28, 857, 10.1007/BF00291078 · DOI
- Amiranoff, 1984, Functional GIP receptors in a hamster pancreatic beta cell line, In 111: specific binding and biological effects, Biochem Biophys Res Commun, 123, 671, 10.1016/0006-291X(84)90281-X · DOI
- Cordonier, 2019, Luciferase reporter mice for in vivo monitoring and ex vivo assessment of hypothalamic signaling of Socs3 expression, J Endocr Soc, 3, 1246, 10.1210/js.2019-00077 · DOI
- Faivre, 2011, Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis, J Neurophysiol, 105, 1574, 10.1152/jn.00866.2010 · DOI · Paper page
- Tian, 2010, Active immunization with glucose-dependent insulinotropic polypeptide vaccine influences brain function and behaviour in rats, Scand J Immunol, 72, 1, 10.1111/j.1365-3083.2010.02400.x · DOI
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“Microglia and astroglia express GIP receptors (128, 129).”
BackgroundObesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Metadata
- Authors
- Fukuda, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2021-06-27
- Volume
- 70
- Issue
- 9
- Pages
- 1929-1937
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3174702068
- Cited by
- 69
- References
- 37
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.